Biotin megadose supplements and laboratory test interference: the FDA warning

← Back to articles

Biotin (vitamin B7) is the most heavily marketed nutrient in the hair, skin, and nails category. Typical product doses range from 1,000 to 10,000 micrograms (mcg) — 33 to 333 times the adult adequate intake of about 30 mcg. Two things are true at once. First, biotin deficiency is essentially nonexistent in adults eating an ordinary diet, so the megadosing has no biological purpose for most users. Second, those megadoses can shift the results of a wide range of laboratory immunoassays — including, in susceptible assay generations, the troponin tests used to diagnose a heart attack. That combination — little upside, a real downstream diagnostic risk — is why the FDA singled the category out.

Why hair, skin, and nail products mega-dose biotin

Frank biotin deficiency does produce hair thinning, brittle nails, and a scaly rash. Marketers extrapolate from those deficiency states to claim that high-dose biotin improves hair and nail quality in well-fed adults. The evidence is thin. A 2017 systematic review of biotin for hair and nail growth found 18 reported cases of benefit, every one of them in a patient with an underlying deficiency or an inherited metabolic disorder; the authors concluded there is no sound evidence for supplementation in otherwise healthy people [1]. The category persists because the product is cheap, the dose looks impressive on the label, and normal hair shedding is easily mistaken for a deficiency.

The laboratory-interference mechanism

Many immunoassays exploit the binding between streptavidin (a bacterial protein) and biotin to capture or detect the target molecule. In a person with normal biotin levels this works as designed. After a recent 10,000-mcg dose, plasma biotin can be high enough to compete with the assay's own biotinylated reagent, and the readout is thrown off. The direction depends on assay format: in competitive immunoassays (used for small molecules such as thyroid hormones) biotin falsely raises the reported value, whereas in sandwich immunoassays (used for many proteins) it falsely lowers it [2]. This is a well-characterized analytical artifact, not a biological effect of biotin on the body.

The troponin concern

The most serious interference involves cardiac troponin, the biomarker used to confirm or exclude a heart attack. Some sandwich-format troponin assays read falsely low when plasma biotin is high, raising the theoretical risk of a missed myocardial infarction. In a controlled study, daily 10-mg biotin produced significant interference in one widely used fifth-generation troponin T assay while leaving two other contemporary assays unaffected, and the interference could be removed by pretreating the sample [3]; other bench work confirms the effect is concentration-dependent [4]. In 2017 the FDA issued a Safety Communication warning that biotin can cause clinically significant incorrect lab results, and noted a report of a patient death linked to a falsely low troponin in someone taking high-dose biotin. Importantly, real-world studies suggest the population risk is small: surveys of routine samples in the US and UK found that only a fraction of a percent reached the biotin concentrations needed to interfere with current troponin assays, and one modeling study put the chance of a biotin-driven false-negative heart-attack result at well under 0.1% [5,6]. The hazard is real but uncommon, and newer assay designs have narrowed it.

Thyroid testing: the most common real-world problem

The interference clinicians actually encounter most often is on thyroid panels. Because TSH uses a sandwich format (falsely low) while free T4 and free T3 use competitive formats (falsely high), high biotin can mimic Graves' disease — low TSH with high free hormones. Patients have been worked up for hyperthyroidism, and in published cases started on antithyroid drugs, before the artifact was recognized; values normalize far faster after stopping biotin than the hormones' half-lives would allow, which is the giveaway [2,7]. A documented case from a New Zealand endocrine service showed exactly this pattern of factitious Graves' disease resolving once biotin was stopped [8]. The fix is simple: hold biotin and repeat the panel.

Other affected tests

Beyond thyroid and troponin, biotin interference has been reported across many biotin-streptavidin immunoassays, including assays for reproductive and adrenal hormones, parathyroid hormone, 25-hydroxyvitamin D, NT-proBNP, certain tumor markers, and some infectious-disease serologies; the direction of error again depends on the assay format [2,7]. Not every manufacturer's assay is susceptible, and many have been reformulated, but a patient cannot know which platform a given laboratory runs. The safe assumption is that any biotin-based immunoassay could be affected if intake is recent and high.

The dose and timing that matter

A standard multivitamin (about 30 mcg of biotin) does not produce meaningful interference. The doses that do are the 1,000–10,000 mcg found in hair-and-nail products, and especially the therapeutic 100–300 mg/day regimens that have been studied in multiple sclerosis. After a high dose, plasma biotin and the potential for interference fall over roughly a day or two as the vitamin is cleared, so most guidance recommends stopping high-dose biotin for at least two to three days before testing.

What patients and clinicians should do

Anyone taking biotin should disclose it before any blood test, and should hold high-dose biotin for two to three days before planned thyroid or cardiac-biomarker testing. In an emergency where supplement use is not volunteered, a discordant picture — biochemical "hyperthyroidism" without clinical signs, or chest pain with a stubbornly negative troponin despite high pre-test probability — should prompt a question about biotin. Many laboratories now ask about it as a routine pre-analytical step. The practical takeaway: for nearly everyone, the right dose of biotin is the small amount already in food and a multivitamin, and the right way to read a mega-dose product is as a source of diagnostic confusion rather than a hair remedy.

Sources

1. Patel DP, Swink SM, Castelo-Soccio L. "A Review of the Use of Biotin for Hair Loss." Skin Appendage Disord, 2017;3(3):166-169. PMID 28879195.
2. Dasgupta A. "Immunoassay design and biotin interference." Adv Clin Chem, 2022;109:165-183. PMID 35953126.
3. Frame IJ, Joshi PH, Mwangi C, et al. "Susceptibility of Cardiac Troponin Assays to Biotin Interference." Am J Clin Pathol, 2019;151(5):486-493. PMID 30715102.
4. Schrapp A, Fraissinet F, Hervouet C, Girot H, Brunel V. "Biotin and high-sensitivity cardiac troponin T assay." Biochem Med (Zagreb), 2018;28(3):030901. PMID 30429682.
5. Mumma B, Diercks D, Twerenbold R, et al. "Clinical risk assessment of biotin interference with a high-sensitivity cardiac troponin T assay." Clin Chem Lab Med, 2020;58(11):1931-1940. PMID 32804676.
6. Sanders A, Gama R, Ashby H, Mohammed P. "Biotin immunoassay interference: A UK-based prevalence study." Ann Clin Biochem, 2021;58(1):66-69. PMID 32936669.
7. Ghazal K, Brabant S, Prie D, Piketty ML. "Hormone Immunoassay Interference: A 2021 Update." Ann Lab Med, 2022;42(1):3-23. PMID 34374345.
8. Elston MS, Sehgal S, Du Toit S, Yarndley T, Conaglen JV. "Factitious Graves' Disease Due to Biotin Immunoassay Interference—A Case and Review of the Literature." J Clin Endocrinol Metab, 2016;101(9):3251-3255. PMID 27362288.
9. U.S. Food and Drug Administration. "The FDA Warns that Biotin May Interfere with Lab Tests: FDA Safety Communication." fda.gov, 2017 (updated 2019).